ARA-290 belongs to the class of erythropoietin derivatives known as EPO-mimetic peptide (EMP) agents. Unlike EPO, Ara-290 has been designed to selectively target the tissue-protective receptor (TPR) without eliciting erythropoiesis, thereby providing cytoprotection without the risk of undesirable hematopoietic side effects. Ara-290 has shown promising results in the treatment of neuropathic pain, particularly in patients with sarcoidosis.
Furthermore, Ara-290 has demonstrated beneficial effects in the treatment of diabetic neuropathy and myocardial infarction. It reduced neuronal loss, improved nerve function, and enhanced myocardial repair and functional recovery in animal models.
Showing all 3 results
[1] https://pubmed.ncbi.nlm.nih.gov/25387363/
[2] https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC3563705/
[3] https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC3883966/
[4] https://www.tandfonline.com/doi/ full/10.1517/21678707.2013.719289
[5] https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC8917853/
[6] https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC4365069/
[7] https://www.sciencedirect.com/science/ article/pii/S074152141301238X
[8] https://www.researchgate.net/ publication/310146980
[9] https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC5741312/
DISCLAIMER: We do not supply peptides to any individual under the age of 21. You must be a licensed and qualified healthcare practitioner. Our team of dedicated professionals are committed to providing an extensive range of products used ONLY in the process of laboratory research by responsible trained and professional individuals. All products listed on this website (https://indonesia.direct-peptides.com) and provided through Direct Peptides are intended for laboratory research purposes only. The products listed on this website are NOT for human or animal consumption or ingestion of any kind.
401 N. Mills Ave, Ste B, Orlando, FL 32803, United States